Sexual Dysfunctions, Psychological
Disturbances in sexual desire and the psychophysiologic changes that characterize the sexual response cycle and cause marked distress and interpersonal difficulty. (APA, DSM-IV, 1994)
Subtype terms (6)
More specific conditions that are subtypes of Sexual Dysfunctions, Psychological in the MeSH hierarchy.
- Dyspareunia
19 drugs (14 approved, 5 experimental)
- Erectile Dysfunction
124 drugs (70 approved, 54 experimental)
- Gender Dysphoria
19 drugs (15 approved, 4 experimental)
- Premature Ejaculation
30 drugs (17 approved, 13 experimental)
- Sexual and Gender Disorders
- Vaginismus
1 drug approved
Drugs by status
Approved for this indication (2)
Phase 4 trials (4)
Phase 3 trials (6)
Phase 2 trials (4)
Phase 1 trials (1)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (7)
Organization Involved with Phase 3 Indications (17)
- Palatin Technologies
- BioSante Pharmaceuticals
- EndoCeutics Inc.
- GlaxoSmithKline
- Boehringer Ingelheim
- QualiLife Pharmaceuticals
- Segraves, R., T., M.D., Ph.D.
- Warner Chilcott
- Case Western Reserve University
- Monash University
- IVIX Ltd.
- Procter and Gamble
- Pharmaceutical Research Associates, Inc. (PRA)
- Ben Gurion University
- Kinsey Institute for Research in Sex, Gender and Reproduction
- Maryland Center for Sexual Health
- Laboratorios LITAPHAR, S.L.
Organization Involved with Phase 2 Indications (13)
- Acerus Pharmaceuticals Corporation
- Pfizer
- Vivus
- Center for Vulvovaginal Disorders
- Emotional Brain NY Inc.
- S1 Biopharma, Inc.
- Strategic Science & Technologies, LLC
- National Center for Complementary and Integrative Health (NCCIH)
- Baylor University
- University of Malaya
- Levine, Risen & Associates, Inc.
- Katz and Kade, Inc.
- The University of Texas, Dallas
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (4)